Jeffrey J Swigris,1 Luca Richeldi,2 Marlies Wijsenbeek,3 Michael Kreuter,4 Hilario Nunes,5 Takafumi Suda,6 Alexandra James,7 Klaus B Rohr,7 Manuel Quaresma,7 Kevin R Flaherty8 on behalf of the INBUILD trial investigators
1National Jewish Health, Denver, CO, USA; 2Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy; 3Department of Respiratory Medicine, Erasmus MC, University Medical Centre, Rotterdam, the Netherlands; 4Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany; 5Department of Pulmonology, Hôpital Avicenne, APHP, Bobigny, France; 6Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; 7Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 8University of Michigan, Ann Arbor, MI, USA
Introduction
- Dyspnea, cough and fatigue can affect the emotional and physical well-being of patients with fibrosing ILDs.1
- In the INBUILD trial in patients with chronic fibrosing ILDs and a progressive phenotype (other than idiopathic pulmonary fibrosis [IPF]), nintedanib slowed the rate of decline in FVC compared with placebo, with adverse events that were manageable for most patients.2
- Changes in health-related quality of life (HRQL) measured using the King’s Brief Interstitial Lung Disease (K-BILD) questionnaire were small, with no meaningful difference between treatment groups.2 Other novel questionnaires were also used to assess changes in symptoms and HRQL during the trial.